Health Care/Hospital
VSA Signs Letter of Intent to Acquire HopeAI, Accelerating Expansion into AI in Life Science
BEIJING, June 17, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (Nasdaq: VSA) (the "Company" or "VSA") today announced that it has entered into a non-binding letter of intent ("LOI") to acquire HopeAI Inc. ("HopeAI"), a leading artificial intelligence company specializing in AI-powered clinica...
2025-06-17 16:30
4548
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022
(RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage --
SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2025-06-17 12:48
2419
CodeSteri Launches PlaDeo: The World's First Bio-Plasma Powered Deodorant Device
A Breakthrough in Underarm Odor Control and Axillary Bromhidrosis Treatment SEOUL, South Korea, June 16, 2025 /PRNewswire/ -- CodeSteri Inc., a tech-driven startup based at theHanyang University College of Medicine in Seoul , today announced the launch ofPlaDeo, the world's first electronic deodor...
2025-06-17 01:00
1939
HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China
NANJING, China, June 16, 2025 /PRNewswire/ -- HELP Therapeutics, a global leader in regenerative medicine, and China Resources Sanjiu Pharmaceutical Company, one ofChina's largest pharmaceutical companies, have announced a strategic partnership to co-develop and commercialize the investigational ...
2025-06-16 22:40
2983
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
* Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma * Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 * Partnership leverages stra...
2025-06-16 21:03
2616
American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence
VANCOUVER, BC, June 16, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation's (AMF) updated Device Corner, a patient education resource highlighting FDA-cleared neuromodulation de...
2025-06-16 21:00
3553
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments...
2025-06-16 20:33
2260
BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
* BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) , followingGMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and Argentina—further strengthening its global prese...
2025-06-16 20:30
1985
"Luminous Path, Shared Stride - Brazil and China"
SHANGHAI, June 16, 2025 /PRNewswire/ -- Brazil's HIHUB.TECH delegation embarked on a landmark visit toShanghai, exploring cutting-edge advancements in healthcare and aesthetic medicine. The delegation's first stop was Zhongshan Hospital, a world-renowned medical institution consistently ranke...
2025-06-16 20:08
2783
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel ...
2025-06-16 20:00
2180
Flat Medical Partners with Mercury Medical for US Distribution of EpiFaith Smart Syringe
Strategic Partnership Brings Breakthrough Epidural Safety Technology to US Anesthesia Market AUSTIN, Texas, June 16, 2025 /PRNewswire/ -- Flat Medical, a pioneering medtech company specializing in innovative safety solutions for anesthesia and pain medicine, today announced it has signed a deale...
2025-06-16 20:00
1728
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...
2025-06-16 19:00
1862
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...
2025-06-16 19:00
2547
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-06-16 10:56
2754
SDP Japan Raises $31 Million in Series D Round
* Pioneering the Future of Surgical Care in Response to Rising Demand TOKYO, June 15, 2025 /PRNewswire/ -- SDP Japan, Inc. (Shibuya-ku, Tokyo; CEO: Kazuhiko Nagayo), announced today that the Company has successfully raised approximately JPY 4.5 billion (equivalent to USD 31 million) through a S...
2025-06-16 10:00
2371
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or ...
2025-06-16 09:25
1979
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
* Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg * The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syrin...
2025-06-16 07:30
2179
Samsung Biologics launches drug screening services, Samsung Organoids
* Samsung Organoids to provide data-driven analysis of candidate molecules * Samsung Biologics expands service scope to include preclinical research INCHEON,South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organizat...
2025-06-16 07:30
2333
Yesoul R1M PLUS Home Rowing Machine: A Full-Body Fitness Solution Designed for Men's Health and Everyday Life
HONG KONG, June 14, 2025 /PRNewswire/ -- Coinciding with Men's Health Month, Yesoul promotes accessible home fitness tailored for today's busy men—from young professionals to active retirees. Prioritizing Men's Health: Why It Matters More Than Ever June is recognized globally as Men's Health Mon...
2025-06-14 19:00
3729
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including pr...
2025-06-13 21:01
3717
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 289 media titles]
2026-04-16 15:34
Silicon Box Announces It Joins Imec Automotive Chiplet Program to Strengthen Chip Supply Chains for Next-Generation Vehicles
[Picked up by 288 media titles]
2026-04-15 21:02
Most Read
Blaize Announces Expected First Quarter 2026 Revenue and Newly Awarded Contract with NeoTensr Anticipated to Generate $50.0 Million in Revenue
2026-04-14 21:43
6195
NYSE Content Update: U.S.-Based Diversified Energy to Ring Bell for 25 Years Since its Founding
2026-04-13 21:06
5650
Makerfire Adopts Breakthrough USX51 Industrial-Grade AI Flight Controller: Empowering Enterprises to Cut Costs and Boost Efficiency in Low-Altitude Operations
2026-04-11 01:00
5508
OCI Global Publishes 2025 Annual Report and Audited Financial Statements
2026-04-11 00:49
5001